Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity

This publication has 58 references indexed in Scilit:

• Antigen‐specific immunotherapy of cervical and ovarian cancer
  Immunological Reviews, 2008
• A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2
  Journal of Virology, 2007
• Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2
  Journal of Virology, 2007
• Association of cervical cancer with the presence of CD4⁺regulatory T cells specific for human papillomavirus antigens
  Proceedings of the National Academy of Sciences, 2007
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
  British Journal of Cancer, 2006
• How will HPV vaccines affect cervical cancer?
  Nature Reviews Cancer, 2006
• Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic Vaccination
  The Journal of Infectious Diseases, 2005
• Against which human papillomavirus types shall we vaccinate and screen? the international perspective
  International Journal of Cancer, 2004
• Papillomaviruses and cancer: from basic studies to clinical application
  Nature Reviews Cancer, 2002
• Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
  European Journal of Immunology, 1993